atai Life Sciences (ATAI)
(Delayed Data from NSDQ)
$1.16 USD
+0.10 (9.43%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $1.16 0.00 (0.00%) 7:28 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Balance Sheet
Fiscal Year End for atai Life Sciences NV falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 179 | 273 | 362 | 97 | 30 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 1 | 0 | 1 | 0 | 8 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 14 | 12 | 2 | 1 |
Total Current Assets | 186 | 287 | 375 | 100 | 39 |
Net Property & Equipment | 1 | 1 | 0 | 0 | 0 |
Investments & Advances | 92 | 7 | 28 | 8 | 23 |
Other Non-Current Assets | 11 | 7 | 4 | 2 | 0 |
Deferred Charges | 0 | 0 | 0 | 2 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 3 | 3 | 7 | 0 | 0 |
Total Assets | 293 | 305 | 414 | 112 | 62 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 2 | 6 | 3 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 15 | 17 | 15 | 9 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 20 | 20 | 21 | 12 | 2 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 3 | 0 | 1 | 2 | 0 |
Long-Term Debt | 15 | 15 | 0 | 0 | 0 |
Non-Current Capital Leases | 1 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 10 | 5 | 7 | 2 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 49 | 40 | 28 | 16 | 2 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 19 | 19 | 18 | 13 | 11 |
Capital Surplus | 795 | 774 | 725 | 262 | 70 |
Retained Earnings | -551 | -510 | -358 | -190 | -20 |
Other Equity | -18 | -17 | 1 | 10 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 244 | 266 | 386 | 95 | 60 |
Total Liabilities & Shareholder's Equity | 293 | 305 | 414 | 112 | 62 |
Total Common Equity | 244 | 266 | 386 | 95 | 60 |
Shares Outstanding | 166.00 | 165.80 | 160.30 | NA | NA |
Book Value Per Share | 1.47 | 1.60 | 2.41 | 0.00 | 0.00 |
Fiscal Year End for atai Life Sciences NV falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 103 | 111 | 179 | 209 | 227 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 10 | 1 | 1 | 0 | 9 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 6 | 6 | 7 | 6 |
Total Current Assets | 118 | 118 | 186 | 216 | 243 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 1 |
Investments & Advances | 94 | 133 | 92 | 75 | 4 |
Other Non-Current Assets | 0 | 14 | 11 | 12 | 1 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 3 | 3 | 3 | 3 |
Total Assets | 216 | 269 | 293 | 308 | 254 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 4 | 5 | 6 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 13 | 11 | 15 | 13 | 13 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 0 | 0 | 1 | 1 |
Total Current Liabilities | 18 | 15 | 20 | 20 | 18 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 3 | 5 | 3 | 0 | 0 |
Long-Term Debt | 15 | 15 | 15 | 15 | 15 |
Non-Current Capital Leases | 1 | 1 | 1 | 1 | 1 |
Other Non-Current Liabilities | 10 | 10 | 4 | 4 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 47 | 46 | 49 | 40 | 38 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 19 | 19 | 19 | 19 | 19 |
Capital Surplus | 803 | 801 | 795 | 799 | 792 |
Retained Earnings | -635 | -578 | -551 | -533 | -577 |
Other Equity | -19 | -18 | -18 | -17 | -18 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 169 | 223 | 244 | 269 | 216 |
Total Liabilities & Shareholder's Equity | 216 | 269 | 293 | 308 | 254 |
Total Common Equity | 169 | 223 | 244 | 269 | 216 |
Shares Outstanding | 167.40 | 167.40 | 166.00 | 166.00 | 166.00 |
Book Value Per Share | 1.01 | 1.33 | 1.47 | 1.62 | 1.30 |